Cargando…
Severe autoimmune intravascular hemolytic anemia in patients receiving alemtuzumab for multiple sclerosis
Autores principales: | Sharma, Parth, Saksena, Annapurna, Diaz, Adolfo, Pang, Yifan, Desai, Parth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248092/ https://www.ncbi.nlm.nih.gov/pubmed/36375041 http://dx.doi.org/10.1182/bloodadvances.2022008968 |
Ejemplares similares
-
Alemtuzumab Plus Cyclosporine Treatment of the Autoimmune Hemolytic Anemia in an Adult Bowel Transplant
por: Lauro, A., et al.
Publicado: (2014) -
Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion
por: Tzartos, John S., et al.
Publicado: (2020) -
Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia
por: Fattizzo, Bruno, et al.
Publicado: (2022) -
Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016) -
Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis
por: Alamo, Angela, et al.
Publicado: (2019)